User profiles for Katrin Heider
 | Katrin HeiderResearch Associate, University of Cambridge Verified email at cruk.cam.ac.uk Cited by 1466 |
Enhanced detection of circulating tumor DNA by fragment size analysis
Existing methods to improve detection of circulating tumor DNA (ctDNA) have focused on
genomic alterations but have rarely considered the biological properties of plasma cell-free …
genomic alterations but have rarely considered the biological properties of plasma cell-free …
ctDNA monitoring using patient-specific sequencing and integration of variant reads
Circulating tumor-derived DNA (ctDNA) can be used to monitor cancer dynamics noninvasively.
Detection of ctDNA can be challenging in patients with low-volume or residual disease, …
Detection of ctDNA can be challenging in patients with low-volume or residual disease, …
Fragmentation patterns and personalized sequencing of cell‐free DNA in urine and plasma of glioma patients
Glioma‐derived cell‐free DNA (cfDNA) is challenging to detect using liquid biopsy because
quantities in body fluids are low. We determined the glioma‐derived DNA fraction in …
quantities in body fluids are low. We determined the glioma‐derived DNA fraction in …
Characteristics, origin, and potential for cancer diagnostics of ultrashort plasma cell-free DNA
Current evidence suggests that plasma cell-free DNA (cfDNA) is fragmented around a mode
of 166 bp. Data supporting this view has been mainly acquired through the analysis of …
of 166 bp. Data supporting this view has been mainly acquired through the analysis of …
[HTML][HTML] Comprehensive characterization of cell-free tumor DNA in plasma and urine of patients with renal tumors
Background Cell-free tumor-derived DNA (ctDNA) allows non-invasive monitoring of
cancers, but its utility in renal cell cancer (RCC) has not been established. Methods Here, a …
cancers, but its utility in renal cell cancer (RCC) has not been established. Methods Here, a …
Detection of ctDNA from dried blood spots after DNA size selection
Background Recent advances in the study and clinical applications of circulating tumor
DNA (ctDNA) are limited by practical considerations of sample collection. Whole-genome …
DNA (ctDNA) are limited by practical considerations of sample collection. Whole-genome …
Comparison of tumor‐informed and tumor‐naïve sequencing assays for ctDNA detection in breast cancer
Abstract Analysis of circulating tumor DNA (ctDNA) to monitor cancer dynamics and detect
minimal residual disease has been an area of increasing interest. Multiple methods have …
minimal residual disease has been an area of increasing interest. Multiple methods have …
Selecting short DNA fragments in plasma improves detection of circulating tumour DNA
Introductory paragraph Non-invasive analysis of cancer genomes using cell-free circulating
tumour DNA (ctDNA) is being widely implemented for clinical indications. The sensitivity for …
tumour DNA (ctDNA) is being widely implemented for clinical indications. The sensitivity for …
Reduction of oral mucositis by palifermin (rHuKGF): dose-effect of rHuKGF
W Dörr, K Heider, K Spekl - International journal of radiation …, 2005 - Taylor & Francis
Purpose: The aim of the present study was to determine the dose effect of palifermin (recombinant
human keratinocyte growth factor, rHuKGF) for reduction of the response of oral …
human keratinocyte growth factor, rHuKGF) for reduction of the response of oral …
Longitudinal monitoring of disease burden and response using ctDNA from dried blood spots in xenograft models
Whole‐genome sequencing (WGS) of circulating tumour DNA (ctDNA) is now a clinically
important biomarker for predicting therapy response, disease burden and disease progression. …
important biomarker for predicting therapy response, disease burden and disease progression. …
